Please assess the completion status of the following clinical trial:

Trial Title: Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male ≥ 4 years and \<10 years of age~* Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon 53 to restore the dystrophin mRNA reading frame;~* Able to walk independently without assistive devices;~* Ability to complete the time to stand, time to run/walk and time to climb assessments;~* Stable dose of glucocorticoid for at least 3 months~Exclusion Criteria:~* Acute illness within 4 weeks prior to the first dose of study medication;~* Evidence of symptomatic cardiomyopathy. \[Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary\];~* Severe allergy or hypersensitivity to medications;~* Severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;~* Previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator;~* Patient is taking any other investigational drug currently or within 3 months prior to the start of study treatment; or~* Patient has had surgery within the 3 months prior to the first anticipated administration of study medication or surgery is planned for anytime during the duration of the study;~* Patient has previously participated in this study or any other study during which NS-065/NCNP-01 was administered.

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- NS-065/NCNP-01 40mg/kg (Type: EXPERIMENTAL): Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 40mg/kg dose once a week for 24 weeks
- NS-065/NCNP-01 80mg/kg (Type: EXPERIMENTAL): Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 80mg/kg once a week for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Two patients in each of the dose groups will be administered placebo as an intravenous infusion once a week for 4 weeks followed by 20 weeks of open label treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).